3-Iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase

被引:32
作者
Benjahad, A
Guillemont, J
Andries, K
Nguyen, CH
Grierson, DS
机构
[1] Inst Curie, UMR 176 CNRS, Lab Pharmacochim, Sect Rech, F-91405 Orsay, France
[2] Johnson & Johnson Pharmaceut Res & Dev, Virol Drug Discovery, B-2340 Beerse, Belgium
[3] Johnson & Johnson Pharmaceut Res & Dev, Dept Med Chem, Val De Reuil, France
关键词
D O I
10.1016/j.bmcl.2003.09.045
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Building upon the potent anti-HIV-1 activities observed for the 3-dimethylamino-4-benzylpyridinone 2, and the corresponding 4-aryloxypyridinone analogue 3, a concise and efficient route to the 3-iodo-4-aryloxypyridinones 14a-c (IOPY's) was developed. This involved reaction of the 4-hydroxy substituted pyridinone 10 with the requisite dichloroiodobenzene reagent 11. IOPY compound 14c is active at IC50 = 1-45 nM against wild type HIV-1 and a panel of six major simple/double HIV mutant strains. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4309 / 4312
页数:4
相关论文
共 18 条
  • [1] NUCLEOPHILIC DISPLACEMENT REACTIONS IN AROMATIC SYSTEMS .1. KINETICS OF THE REACTIONS OF CHLORONITROPYRIDINES WITH AROMATIC AMINES AND WITH PYRIDINE
    BISHOP, RR
    CAVELL, EAS
    CHAPMAN, NB
    [J]. JOURNAL OF THE CHEMICAL SOCIETY, 1952, (FEB): : 437 - 446
  • [2] Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study
    Carr, A
    Samaras, K
    Thorisdottir, A
    Kaufmann, GR
    Chisholm, DJ
    Cooper, DA
    [J]. LANCET, 1999, 353 (9170) : 2093 - 2099
  • [3] Adverse effects of antiretroviral therapy
    Carr, A
    Cooper, DA
    [J]. LANCET, 2000, 356 (9239) : 1423 - 1430
  • [4] New developments in anti-HIV chemotherapy
    De Clercq, E
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2002, 1587 (2-3): : 258 - 275
  • [5] Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors
    Dollé, V
    Nguyen, CH
    Legraverend, M
    Aubertin, AM
    Kirn, A
    Andreola, ML
    Ventura, M
    Tarrago-Litvak, L
    Bisagni, E
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (21) : 3949 - 3962
  • [6] A NEW SERIES OF PYRIDINONE DERIVATIVES AS POTENT NONNUCLEOSIDE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SPECIFIC REVERSE-TRANSCRIPTASE INHIBITORS
    DOLLE, V
    FAN, E
    NGUYEN, CH
    AUBERTIN, AM
    KIRN, A
    ANDREOLA, ML
    JAMIESON, G
    TARRAGOLITVAK, L
    BISAGNI, E
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (23) : 4679 - 4686
  • [7] ELMARIAH FAA, 1986, CROAT CHEM ACTA, V59, P171
  • [8] Initial therapy of HIV infection
    Gallant, JE
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2002, 25 (03) : 317 - 333
  • [9] Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants
    Hopkins, AL
    Ren, JS
    Tanaka, H
    Baba, M
    Okamato, M
    Stuart, DI
    Stammers, DK
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (22) : 4500 - 4505
  • [10] The Lys103Asn mutation of HIV-1 RT:: A novel mechanism of drug resistance
    Hsiou, Y
    Ding, JP
    Das, K
    Clark, AD
    Boyer, PL
    Lewi, P
    Janssen, PAJ
    Kleim, JP
    Rösner, M
    Hughes, SH
    Arnold, E
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2001, 309 (02) : 437 - 445